In 2015, Tie et al. [99] reported that the patient-specific candidate mutations, such as KRAS G13D, in CRC tissues were detectable in the cfDNAs from 48 of 52 patients (concordance, 92.3%). Here, KRAS is linked to colorectal carcinoma.